A major new clinical trial called PRECISE-HD has started to test whether a drug called pridopidine can help people with Huntington’s disease. The study is being run by two pharmaceutical companies, Ferrer and Prilenia, and is now recruiting participants in the United States, with plans to expand to Europe, the United Kingdom, and Canada later this year. The trial aims to include 400 people who have early to mid-stage Huntington’s disease, with the hope of confirming if pridopidine can slow down the progression of the disease and improve symptoms like movement, thinking, speech, and overall quality of life. Pridopidine is taken as a pill twice a day, and the study will compare its effects to a placebo (a pill with no active medicine) to see if it truly works. The trial will last for a total of 156 weeks (about 3 years), with the first 52 weeks being a double-blind phase where neither participants nor researchers will know who is taking the real drug or the placebo. After that, all participants will have the option to take pridopidine openly for another 104 weeks to see if the drug’s effects last over time. The study is designed with input from patient groups, the Huntington’s disease community, and experts to make sure it measures meaningful changes in the disease. Astri Arnesen, President of the European Huntington Association, shared her excitement about the study, saying it’s a much-needed step to confirm previous findings and that the community’s feedback was valued in shaping the trial. Victor Sung, a leading researcher on the study, added that pridopidine has shown promise in earlier research, and this new study is carefully designed to provide clear answers. Oscar Pérez, a chief scientist at Ferrer, emphasized that this trial is part of their ongoing efforts to develop treatments for rare neurological diseases where there is still a great need for better options.